Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
RESEARCH TOOLSreports
Holding ATRA?
Track your performance easily
ATRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.50 - $39.50
Previous Close$10.68
Volume25.05K
Average Volume (3M)147.99K
Market Cap
$60.34M
Enterprise Value$31.35M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$35.24M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Mar 03, 2025EPS Estimate
-$3.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.66
Shares Outstanding5,759,750
10 Day Avg. Volume150,646
30 Day Avg. Volume147,993
Standard Deviation0.26
R-Squared0.00974
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.68
Price to Sales (P/S)0.63
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit-100.17
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$15.50Price Target Upside52.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Atara Biotherapeutics News
PremiumCompany Announcements
Atara Biotherapeutics Reports Q3 2024 Financial Progress
PremiumCompany Announcements
Atara Biotherapeutics Advances with Strategic Partnerships
PremiumCompany Announcements
Atara Biotherapeutics Appoints Eric Hyllengren as COO
Bulls Say, Bears Say
Bulls Say
Cash Runway ExtensionCash, cash equivalents, and short-term investments totaled $73.2 million at the end of 2Q24, including $20M milestone and $15.5M tab-cel inventory sale, which the company expects will be sufficient to fund operations into 2027.
FDA ApprovalThe FDA accepted for review its Biologics License Application (BLA) for approval of tabelecleucel (tab-cel) for the treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Milestone PaymentShould the FDA approve tab-cel, Atara will receive a $60M milestone payment from Pierre Fabre.
Bears Say
EarningsAtara recorded a net loss of $3.10 per share versus a prior forecast for net earnings of $0.06 per share.
Earnings ProjectionProjected full-year 2024 net loss is $16.63 per share compared to a prior estimate of a net loss of $0.73 per share.
Regulatory RisksRisks include setbacks such as the failure of tab-cel in EBV+ PTLD patients in trials, inability to file the Biologics License Application for tab-cel on time, and potential rejection of the BLA by the FDA.
---
Ownership Overview
33.52% Insiders
7.32% Mutual Funds
20.40% Other Institutional Investors
35.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $6.50 and its highest was $39.50 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 102 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$1.888 by -$1.042.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -$3.32.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,759,750 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$1.888. Following the earnings report the stock price went up 22.194%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at N/A.
---
Atara Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (52.26% Upside)
$15.50 (52.26% Upside)
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.41%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
ATRA Earnings Call
Q3 2023
0:00 / 0:00
---
ATRA Stock 12 Month Forecast
Average Price Target
$15.50
▲(52.26% Upside)
Technical Analysis
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+2.10%
reiterated a buy rating 9 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +2.10% per trade.
---